While earlier hypotheses suggested that reverse transcriptase inhibitors (RTIs), such as Tenofovir, might reduce amyloid deposition by decreasing amyloid precursor protein (APP) gene copies [76], recent studies indicate that RTI therapy may not provide protection against Alzheimer-type amyloidogenesis in the context of HIV infection [78]. The gene discussed is APP; the disease is HIV infectious disease.